Fundraising Fox
/Companies
Sign in

Cornerstone Pharmaceuticals

Cranbury,, US · 19 employees on LinkedIn

Find your way into Cornerstone Pharmaceuticals

Sign up to see every warm intro you have to Cornerstone Pharmaceuticals

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cornerstone Pharmaceuticals team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Cornerstone Pharmaceuticals develops anti-metabolic cancer therapies and is testing its lead drug candidate, CPI-613 (devimistat), in combinations using preclinical cancer models.

BiotechHealthtech

Founders & leadership

RS
Robert ShorrFounder
DADavid A. Polinsky
David A. PolinskyCo-Founder, President, and General Counsel2002–2018David A. Polinsky previously served as Chief Financial Officer at Rafael Holdings, a publicly-traded biotechnology company, where he oversaw finance, legal, and corporate strategy. He holds a Juris Doctorate from Fordham University School of Law and has over 25 years of experience in senior management at private and public companies, including co-founding and leading multiple startups through various development stages.
RR
Robert RodriguezExecutive
CH
Clifford H StraubExecutive

Board

PS
Patrick S. WilmerdingBoard director
HJ
Howard JonasBoard director
JA
Joseph A. SternBoard director
AD
Aaron DrillickBoard director
SF
Sim FassBoard director
HG
Herman Gilbert PolinskyBoard director

Reported raises · per SEC filings

Form D private placements

$3.3M disclosed across 1 round · 2014

▶$3.3MraisedMar 2014 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick S. WilmerdingDirector
  • Howard JonasDirector
  • Joseph A. SternDirector
  • Robert ShorrExecutive Officer, Director
  • Aaron DrillickDirector
  • Sim FassDirector
  • David A. PolinskyExecutive Officer, Director
  • Herman Gilbert PolinskyDirector
  • Robert RodriguezExecutive Officer, Director
  • Clifford H StraubExecutive Officer
Offering amount
$7.5M
Amount sold
$3.3M
Proceeds to insiders
$1.9M
First sale
Feb 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Cornerstone Pharmaceuticals, Inc. Receives Funding Through New Jersey's Technology Business Tax Certificate Transfer Program - BioSpacebiospace.com · Jan 2015Cancer Metabolism Therapeutics Innovator, Cornerstone Pharmaceuticals, Announces Completion of More Than $6MM in Private Equity Financingprnewswire.com · Jan 2010

Frequently asked questions

What does Cornerstone Pharmaceuticals do?
Cornerstone Pharmaceuticals develops anti-metabolic cancer therapies and is testing its lead drug candidate, CPI-613 (devimistat), in combinations using preclinical cancer models.
Who founded Cornerstone Pharmaceuticals?
Cornerstone Pharmaceuticals was founded by Robert Shorr.
How much funding has Cornerstone Pharmaceuticals raised?
Cornerstone Pharmaceuticals has disclosed $3.3M raised across 1 round.
Where is Cornerstone Pharmaceuticals headquartered?
Cornerstone Pharmaceuticals is headquartered in Cranbury,, US.